Allopurinol kinetics
- PMID: 639435
- DOI: 10.1002/cpt1978235598
Allopurinol kinetics
Abstract
A spectrophotometric assay for measuring allopurinol and oxipurinol has been developed which can detect as little as 5 X 10(-8) M of each in serum and urine. With this assay, serum disappearance characteristics of intravenous and orally administered allopurinol have been investigated in man. Serum concentrations of both allopurinol and oxipurinol reach levels above 1 X 10(-5) M within minutes of intravenous administration and within 1 or 2 hr of oral administration of 300 mg allopurinol. Patients receiving 300 mg allopurinol daily show a mean serum concentration of 3 X 10(-5) M oxipurinol (range, 0.9 to 9 X 10(-5) M). Serum half-lives of allopurinol and oxipurinol were 39 +/- 11 min and 13.6 +/- 2.8 hr, respectively. Estimates of renal clearance were 13.6 and 18.9 ml/min for allopurinol and 23.2 and 30.6 ml/min for oxipurinol in 2 patients studied. The metabolic conversion of allopurinol to oxipurinol in man does not appear to be altered by long-term therapy with allopurinol, which suggests that this conversion takes place by way of an enzymatic reaction not strongly inhibited by either substrate or product. These results suggest the possibility of a nonxanthine oxidase enzymatic pathway for this conversion.
Similar articles
-
Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide.Eur J Clin Pharmacol. 1982;22(1):77-84. doi: 10.1007/BF00606429. Eur J Clin Pharmacol. 1982. PMID: 7094977
-
Allopurinol kinetics and bioavailability. Intravenous, oral and rectal administration.Cancer Chemother Pharmacol. 1982;8(1):93-8. doi: 10.1007/BF00292878. Cancer Chemother Pharmacol. 1982. PMID: 7094203
-
Kinetics of allopurinol and oxipurinol after chronic oral administration. Interaction with benzbromarone.Eur J Clin Pharmacol. 1986;31(1):53-8. doi: 10.1007/BF00870986. Eur J Clin Pharmacol. 1986. PMID: 3780828
-
Oxipurinol: alloxanthine, Oxyprim, oxypurinol.Drugs R D. 2004;5(3):171-5. doi: 10.2165/00126839-200405030-00008. Drugs R D. 2004. PMID: 15139781 Review.
-
Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.Clin Pharmacokinet. 2007;46(8):623-44. doi: 10.2165/00003088-200746080-00001. Clin Pharmacokinet. 2007. PMID: 17655371 Review.
Cited by
-
Use and abuse of allopurinol.Br Med J (Clin Res Ed). 1987 Jun 13;294(6586):1504-5. doi: 10.1136/bmj.294.6586.1504. Br Med J (Clin Res Ed). 1987. PMID: 3607420 Free PMC article. No abstract available.
-
Interaction of allopurinol and hydrochlorothiazide during prolonged oral administration of both drugs in normal subjects. I. Uric acid kinetics.Clin Investig. 1994 Dec;72(12):1071-5. doi: 10.1007/BF00577758. Clin Investig. 1994. PMID: 7711418
-
Pharmacokinetic/Pharmacodynamic Modelling of Allopurinol, its Active Metabolite Oxypurinol, and Biomarkers Hypoxanthine, Xanthine and Uric Acid in Hypoxic-Ischemic Encephalopathy Neonates.Clin Pharmacokinet. 2022 Feb;61(2):321-333. doi: 10.1007/s40262-021-01068-0. Epub 2021 Oct 7. Clin Pharmacokinet. 2022. PMID: 34617261 Free PMC article. Clinical Trial.
-
Pharmacokinetic parameters of 14C oxithiopurinol in rat.Eur J Drug Metab Pharmacokinet. 1979;4(2):59-65. doi: 10.1007/BF03189402. Eur J Drug Metab Pharmacokinet. 1979. PMID: 488133
-
Allopurinol dosage selection: relationships between dose and plasma oxipurinol and urate concentrations and urinary urate excretion.Br J Clin Pharmacol. 1988 Oct;26(4):423-8. doi: 10.1111/j.1365-2125.1988.tb03401.x. Br J Clin Pharmacol. 1988. PMID: 3190992 Free PMC article.